Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | TYMP | P19971 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4577748 | 0.86 | EPHX1 (0.48) | EPHX1EPHX2KDM1ARIPK1 | |
| SCHEMBL14330457 | 0.83 | EPHX1 (0.46) | EPHX1EPHX2KDM1A | |
| SCHEMBL4577744 | 0.82 | EPHX1 (0.48) | EPHX1EPHX2KDM1ARIPK1 | |
| SCHEMBL7477572 | 0.81 | EPHX1 (0.45) | EPHX1EPHX2KDM1ARIPK1 | |
| SCHEMBL16095553 | 0.81 | EPHX1 (0.47) | EPHX1EPHX2KDM1ARIPK1 | |
| SCHEMBL13754851 | 0.81 | EPHX1 (0.47) | EPHX1EPHX2KDM1ARIPK1 | |
| SCHEMBL13597237 | 0.80 | POLB (0.48) | EPHX1EPHX2 | |
| SCHEMBL27922619 | 0.79 | AKR1C3 (0.44) | AKR1C3TYMP | |
| SCHEMBL4100243 | 0.79 | EPHX2 (0.43) | EPHX1EPHX2KDM1A | |
| SCHEMBL18667410 | 0.79 | EPHX2 (0.43) | EPHX1EPHX2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656971-B2 | COMT inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2938600-B1 | COMT INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-01-25 | — | — | EP | disclosed |
| US-20160002177-A1 | COMT INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2938600-A1 | COMT INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014102233-A1 | COMT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-03 | — | — | WO | disclosed |
| US-20110098241-A1 | RAPAMYCIN ANALOGS AS ANTI-CANCER AGENTS | PONIARD PHARMACEUTICALS, INC. | 2011-04-28 | — | — | US | disclosed |
| WO-2009131631-A1 | RAPAMYCIN ANALOGS AS ANTI-CANCER AGENTS | PONIARD PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002177-A1 | COMT INHIBITORS | COMT, PNMT, SLC6A3 | EPHX1 1481/4885EPHX2 2083/4885AKR1C3 1325/4885 |
| US-20110098241-A1 | RAPAMYCIN ANALOGS AS ANTI-CANCER AGENTS | RICTOR, MTOR, RPTOR | EPHX1 4861/4885EPHX2 4865/4885AKR1C3 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.